NCT02508844View on ClinicalTrials.gov

Effect of Probiotics (Vivomixx®) on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

March 31, 2020

Conditions
PregnancyObesityGestational Diabetes Mellitus
Interventions
DIETARY_SUPPLEMENT

Vivomixx®

probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery

DIETARY_SUPPLEMENT

Placebo

Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.

Trial Locations (1)

2650

Hvidovre University Hospital, Hvidovre

All Listed Sponsors
collaborator

University of Copenhagen

OTHER

collaborator

Statens Serum Institut

OTHER

lead

Hvidovre University Hospital

OTHER

NCT02508844 - Effect of Probiotics (Vivomixx®) on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn | Biotech Hunter | Biotech Hunter